September 22, 2026 | ASCO, Congress, Pharma, healthcare, oncology
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

The pace of innovation in oncology is accelerating, bringing more data, more complex science, and more information for HCPs to navigate.
Our latest oncology congress eBook explores what this means for life sciences organizations and how congress experiences can help turn scientific innovation into understanding.
Discover insights on:
Making meaningful connections in an age of accelerated innovation
Creating more effective congress experiences
The future of congress engagement for life sciences companies
Emerging trends shaping oncology commercialization
Why a connected approach is key to congress success
This content was provided by Inizio
Latest Content from Inizio
In 2001, British economist Jim O’Neill coined the now ubiquitous acronym ‘BRIC’, to stand for the four emerging economies of Brazil, Russia, India and China, which he suggested were all…
As we shake off our winter coats and prepare for what will hopefully be a long, hot summer, the 2014 themes for healthcare and market research are emerging.
Big Data is an exciting by-product of the information technology revolution and offers new ways of understanding customers.
What does the future hold for the US pharma industry?
Pharmaceutical market research is still evolving in many emerging markets and so finding the insights you require can be a challenge.
Pharma companies are increasingly looking for ways to provide “beyond the pill” services to support patients with the management of their disease. Adherence tools and programs encourage patients to stay compliant with their treatment…
Treatment initiation is a key focus for many pharma companies as part of their strategy to increase script writing and drive greater revenues.
One of the most consistent issues researchers face with segmentation is ensuring that it is actionable.
Exploring the opportunities for pharma in the ASEAN region and factors to consider when conducting healthcare market research.
Understanding the opportunities for biosimilars and the threats to innovator biologics
